Financial Data and Key Metrics - Revenue from existing business increased from 9.3milliontoanannualizedrunrateof16 million, with profits expected to be around 3.5million[4]−AdjustedEBITDAandcashflowimprovedsignificantlyinQ12024comparedtoQ42023[31]BusinessLineDataandKeyMetrics−Pharmalozisexpectedtoseesignificantimprovementinthesecondhalfof2024,withfullcapacitydemandforQ3[26]−NebulaGenomicsisprojectedtorampuprevenuesinQ42024orQ12025,withsubstantialpotentialinitsbioinformaticsplatformanddatabase[3][61]−Equivir,adietarysupplement,completedastudywithover300patients,showingpromisingresultsinreducingillnessfromviruseslikeCOVID,flu,andRSV[18][30]MarketDataandKeyMetrics−Pharmalozhasattractedpotentialnewcustomers,includingsmallerbrandsthatcouldfillupthesecondmanufacturingline[6]−TheBE−SmartEsophagealCancertesttargetsamarketof7millionendoscopiesannually,withpotentialinsurancereimbursementof1,000 to 2,000pertest,creatinga7 billion to 14billionmarket[74]CompanyStrategyandIndustryCompetition−ThecompanyisexploringstrategicalternativesforPharmaloz,includingpotentialsalesorpartnerships,after1.5to2yearsofplanningandexecution[5][29]−NebulaGenomicsisdevelopinganewgo−to−marketstrategyleveragingsocialmediaandpodcastexperts,withpotentialcelebrityendorsements[61][75]−TheBE−Smarttestispositionedasabreakthroughincancerdiagnostics,withnodirectcompetitionandmultibillion−dollarpotential[52][97]ManagementCommentaryonOperatingEnvironmentandFutureOutlook−Managementbelievesthecompanyisataturningpoint,withsignificantdevelopmentsexpectedinPharmaloz,Nebula,andtheBE−Smarttest[28][40]−Thecompanyisfocusedonlong−termvaluecreationforshareholders,withnoimmediateplansforequityfinancing[23][103]−ThelabinfrastructureforNebulaGenomicsisseenasastrategicasset,despitecurrentcosts,duetoitspotentialforfuturegrowth[51][110]OtherImportantInformation−Thecompanyhasahistoryofsuccessfulturnarounds,includingthesaleofCold−EEZEfor50 million and IT Biomedical for $1.4 billion [63] - The AI initiative leverages the company’s database and proprietary discoveries, focusing on anti-drug conjugates for cancer treatment [78] Q&A Session Question: Growth plans for Nebula Genomics - Nebula’s growth strategy includes leveraging its bioinformatics platform, database, and social media experts, with revenues expected to ramp up in Q4 2024 or Q1 2025 [61][75][116] Question: Potential IPO for Nebula or Pharmaloz - The company is open to IPOs for Nebula or Pharmaloz under the right market conditions but is cautious about timing to maximize valuation [22][109] Question: Revenue expectations for Q2 2024 - Management does not expect significant revenue growth in Q2, with major improvements anticipated in Q3 for Pharmaloz and Q4 for Nebula [31][87] Question: Claims for Equivir packaging - Claims for Equivir are still being finalized, with the company planning to launch the product online first before expanding to retail stores [86][118] Question: Valuation of CDMO sales licensing transactions - The company declined to provide additional information on CDMO valuation, citing ongoing strategic discussions [24] Question: Potential partnership for BE-Smart - The company is open to exploring partnerships for BE-Smart but is focused on maximizing long-term shareholder value [32][36] Question: Share count increase from 18 million to 90 million - Management did not provide specific details on the share count increase, only noting that shares change over time [111]